Trial intelligence / Profile preview

TUC-TOC

2022-500743-20-00Phase 2Authorised

Sponsor: Institut Curie
Start: Jun 2023
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Countries: 1

Overview

Phase 2, open-label, single-arm trial of tucatinib, autologous adipose-derived mesenchymal stem cells and trastuzumab in HER2-enriched breast cancer (HER2+), sponsored by Institut Curie. Primary endpoint: Objective response rate (ORR). Planned start Jun 2023; status: authorised.

Drugs

tucatinibautologous adipose-derived mesenchymal stem cellstrastuzumab

Conditions

HER2-enriched breast cancer (HER2+)

Beyond the preview

Go deeper on 2022-500743-20-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2022-500743-20-00.